Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  palbociclib
Find trials that include:  Any drugs shown
Results 1-25 of 28 for your search:
Start Over
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400E, S1400A, S1400I, S1400C, S1400D, S1400B, NCT02154490
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: GBG78/BIG 1-13/NSABP-B-54-I, NCI-2014-02553, 2013-001040-62, NCT01864746
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70, Postmenopausal
Trial IDs: A5481027, NCI-2015-01375, JS14185, NCT02297438
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
Palbociclib and Bazedoxifene in Treating Patients with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-060, NCI-2015-01604, WI196579, NCT02448771
Palbociclib and Bicalutamide in Treating Patients with Metastatic Androgen Receptor Positive or Triple Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-207, NCI-2015-02043, NCT02605486
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D2270C00020, NCI-2016-00558, BRE 253, NCT02599714
Palbociclib, Everolimus, and Exemestane in Treating Patients with Estrogen Receptor Positive and HER2 Negative Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-177, NCI-2016-01367, NCT02871791
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201301106, NCI-2012-02202, NCT01723774
Androgen Deprivation Therapy with or without Palbociclib Isethionate in Treating Patients with RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.117, NCI-2014-01922, HUM00082715, NCT02059213
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-11, NCI-2015-00998, WI180455, NCT02296801
Palbociclib in Treating Patients with Metastatic Urothelial Cancer after First-Line Chemotherapy Failure
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1406, NCI-2015-00532, 14-2196, WI187190, NCT02334527
Palbociclib in Combination with Fulvestrant or Tamoxifen Citrate in Treating Patients with Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 147522, NCI-2015-01791, CC#147522, TBCRC035, NCT02384239
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A5481044, NCI-2015-01296, 2015-000515-41, PALATINUS, NCT02499120
Fulvestrant and Palbociclib in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: OSU-15266, NCI-2016-00146, 2016C0015, NCT02760030
Tamoxifen Citrate or Letrozole with or without Palbociclib in Treating Patients with Stage I-III Invasive Breast Cancer before Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-052, NCI-2016-00893, NCT02764541
Palbociclib in Treating Patients with Metastatic HER-2 Positive or Triple-Negative Breast Cancer with Brain Metastasis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 15B08, NCI-2016-00626, STU00202582, NCT02774681
PD-0332991, Fluorouracil, and Oxaliplatin in Treating Patients With Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2011-219, NCI-2013-00658, NCT01522989
Palbociclib Isethionate and Ado-Trastuzumab Emtansine in Treating Patients with Recurrent or Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: SCCC-05113, NCI-2014-00821, Mod13_STU 042013-042, Mod9_STU 042013-042, 042013-042, 8843, NCT01976169
Palbociclib and PD0325901 in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-506, NCI-2014-00940, NCT02022982
Ibrutinib and Palbociclib in Treating Patients with Previously Treated Mantle Cell Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9534, NCI-2014-01202, 1403014853, NCT02159755
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Start Over